Adzenys ER (amphetamine XR oral suspension)
/ Aytu BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 08, 2019
Neos Therapeutics reports third quarter 2019 financial results
(GlobeNewswire)
- "Neos reported growth in net product sales and net revenue per pack for its two core commercial attention deficit hyperactivity disorder (ADHD) products, Adzenys XR-ODT® and Cotempla XR-ODT®, for the three months ended September 30...Adzenys XR-ODT: $122; Cotempla XR-ODT®: $128...Total product revenues were $17.5 million for the three months ended September 30, 2019...Adzenys XR-ODT: $8.8MM; Cotempla XR-ODT: $7.2MM; Adzenys ER: $0.2MM;"
Commercial
1 to 1
Of
1
Go to page
1